Measurement of the Intracellular Mycobacterium tuberculosis Drug Effect and Prediction of the Clinical Dose-Response Relationship Using Intracellular Pharmacodynamic Modeling (PD
Antibiotics
Drug screening
Mycobacteria
Pharmacokinetic and pharmacodynamic drug Modeling
Tuberculosis
Journal
Methods in molecular biology (Clifton, N.J.)
ISSN: 1940-6029
Titre abrégé: Methods Mol Biol
Pays: United States
ID NLM: 9214969
Informations de publication
Date de publication:
2021
2021
Historique:
entrez:
12
5
2021
pubmed:
13
5
2021
medline:
23
6
2021
Statut:
ppublish
Résumé
The human disease tuberculosis (TB) is the leading cause of death from a single infectious agent. A quarter of the world's population is estimated to be latently infected. Drug development and screening is slow and costly. We have developed a physiologically relevant assay to screen drugs against TB when inside immune cells. This chapter will describe a newly developed preclinical drug screening assay for TB, using high-content imaging and pharmacokinetic/pharmacodynamic modeling.
Identifiants
pubmed: 33977461
doi: 10.1007/978-1-0716-1358-0_23
doi:
Substances chimiques
Antitubercular Agents
0
Bacterial Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
393-408Subventions
Organisme : Medical Research Council
ID : MC_PC_17167
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N028376/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/S00467X/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/W004356/1
Pays : United Kingdom
Références
WHO (2019) Global TB report
Donnellan S, Giardiello M (2019) Nanomedicines towards targeting intracellular Mtb for the treatment of tuberculosis. J Interdiscip Nanomedicine 4:1–10
doi: 10.1002/jin2.61
Smith J (2011) Nanoparticle delivery of anti-tuberculosis chemotherapy as a potential mediator against drug-resistant tuberculosis. Yale J Biol Med 84:361–369
pubmed: 22180674
pmcid: 3238330
Verschoor J, Baird M, Grooten J (2012) Towards understanding the functional diversity of cell wall mycolic acids of Mycobacterium tuberculosis. Prog Lipid Res 51:325–339
doi: 10.1016/j.plipres.2012.05.002
Ohara N (2012) Current status of tuberculosis and recombinant bacillus Calmette-Guérin vaccines. J Oral Biosci 54:92–95
doi: 10.1016/j.job.2012.04.002
Gillespie SH (2016) The role of moxifloxacin in tuberculosis therapy. Eur Respir Rev 25:19–28
doi: 10.1183/16000617.0085-2015
Aljayyoussi G, Jenkins VA, Sharma R, Ardrey A, Donnellan S, Ward SA, Biagini GA (2017) Pharmacokinetic-pharmacodynamic modelling of intracellular Mycobacterium tuberculosis growth and kill rates is predictive of clinical treatment duration. Sci Rep 7:502
doi: 10.1038/s41598-017-00529-6
Digby, Mizrahi V (2007) The survival kit of Mycobacterium tuberculosis. Nat Med 13:282–284
doi: 10.1038/nm0307-282
De Steenwinkel JEM, Aarnoutse RE, De Knegt GJ, Ten Kate MT, Teulen M, Verbrugh HA, Boeree MJ, Van Soolingen D, Bakker-Woudenberg IAJM (2013) Optimization of the rifampin dosage to improve the therapeutic efficacy in tuberculosis treatment using a murine model. Am J Respir Crit Care Med 187:1127–1134
doi: 10.1164/rccm.201207-1210OC
Weiner M, Savic RM, Kenzie WR, Wing D, Peloquin CA, Engle M, Bliven E, Prihoda TJ, Gelfond JA, Scott NA, Abdel-Rahman SM, Kearns GL, Burman WJ, Sterling TR, Villarino ME, Tuberculosis Trials Consortium PTBPG (2014) Rifapentine pharmacokinetics and tolerability in children and adults treated once weekly with Rifapentine and isoniazid for latent tuberculosis infection. J Pediatr Infect Dis Soc 3:132–145
doi: 10.1093/jpids/pit077
Ferlazzo G, Mohr E, Laxmeshwar C, Hewison C, Hughes J, Jonckheere S, Khachatryan N, De Avezedo V, Egazaryan L, Shroufi A, Kalon S, Cox H, Furin J, Isaakidis P (2018) Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study. Lancet Infect Dis 18:536–544
doi: 10.1016/S1473-3099(18)30100-2
Bartelink IH, Zhang N, Keizer RJ, Strydom N, Converse PJ, Dooley KE, Nuermberger EL, Savic RM (2017) New paradigm for translational modeling to predict long-term tuberculosis treatment response. Clin Transl Sci 10:366–379
doi: 10.1111/cts.12472
Lanoix E, Chaisson R, Nuermberger E (2016) Shortening tuberculosis treatment with fluoroquinolones: lost in translation? Clin Infect Dis 62:484–490
pubmed: 26527614
Rosenthal IM, Tasneen R, Peloquin CA, Zhang M, Almeida D, Mdluli KE, Karakousis PC, Grosset JH, Nuermberger EL (2012) Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis. Antimicrob Agents Chemother 56:4331–4340
doi: 10.1128/AAC.00912-12
Aljayyoussi G, Donnellan S, Ward SA, Biagini GA (2019) Intracellular PD modelling (PDi) for the prediction of clinical activity of increased rifampicin dosing. Pharmaceutics 11:6–8
doi: 10.3390/pharmaceutics11060278
Donnellan S, Aljayyoussi G, Moyo E, Ardrey A, Martinez-Rodriguez C, Ward SA, Biagini GA (2019) Intracellular pharmacodynamic modelling (PDi) is predictive of the clinical activity of fluoroquinolones against tuberculosis. Antimicrob Agents Chemother 64:1
doi: 10.1128/AAC.00989-19
Boeree MJ, Heinrich N, Aarnoutse R, Diacon AH, Dawson R, Rehal S, Kibiki GS, Churchyard G, Sanne I, Ntinginya NE, Minja LT, Hunt RD, Charalambous S, Hanekom M, Semvua HH, Mpagama SG, Manyama C, Mtafya B, Reither K, Wallis RS, Venter A, Narunsky K, Mekota A, Henne S, Colbers A, van Balen GP, Gillespie SH, Phillips PPJ, Hoelscher M (2017) High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. Lancet Infect Dis 17:39–49
doi: 10.1016/S1473-3099(16)30274-2
Rich JT, Neeley JG, Paniello RC, Voelker CCJ, Oxon DP, Nussenbaum B, Wang EW (2014) A practical Guid to understanding Kaplan-Meier curves. J Otolaryngol Head Neck Surg 143:331–336
doi: 10.1016/j.otohns.2010.05.007
Smith I (2003) Mycobacterium tuberculosis pathogenesis and molecular determinants of virulence. Clin Microbiol Rev 16:463–496
doi: 10.1128/CMR.16.3.463-496.2003
Holford N, Sheiner L (1981) Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet 6:429–454
doi: 10.2165/00003088-198106060-00002